P63 is Required Beside P53 for PERP-mediated Apoptosis in Uveal Melanoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Sep 2

PMID 27584665

Citations 20

Authors

Raheela Awais

David G Spiller

Michael R H White

Luminita Paraoan

Affiliations

Soon will be listed here.

Abstract

Background: PERP (p53 apoptosis effector related to PMP-22), a transcriptional target of p53, is downregulated and contributes to the impairment of apoptosis in uveal melanoma (UM). Intriguingly, PERP is not induced in UM despite functional p53. p63, located on chromosome 3, which is characteristically altered in high-risk UM, can transactivate PERP. Here, we determine the functional role of p63 expression in the initiation of p53/PERP-mediated apoptosis in UM.

Methods: PERP expression was monitored by quantitative PCR (qPCR) and immunoblotting in UM cell lines treated with DNA-damaging agents. The functional role of p63 was assessed by transient expression of p63-turbo GFP (p63-tGFP) in the apoptosis- resistant, 3q-deficient OCM-1 cells. Expression and localisation of p63, PERP and p53, and induction of apoptosis were characterised by qPCR, immunoblotting and live cell confocal microscopy.

Results: PERP expression was significantly downregulated in all UM cell lines. DNA-damaging treatments failed to induce apoptosis and activate PERP in OCM-1 cells, which displayed non-functional levels of p63. Expression of p63-tGFP induced apoptosis with marked increase in PERP expression and associated p53 accumulation.

Conclusions: Lack of p63 contributes to reduced PERP levels and impaired p53-mediated apoptosis in UM. p63 expression is required for PERP-mediated apoptosis in UM.

Citing Articles

Regulation of mA (N-Methyladenosine) methylation modifiers in solid cancers.

Singh S, Gupta S, Abhishek R, Sachan M Funct Integr Genomics. 2024; 24(6):193.

PMID: 39438339 DOI: 10.1007/s10142-024-01467-z.

Single-cell and bulk transcriptional profiling of mouse ovaries reveals novel genes and pathways associated with DNA damage response in oocytes.

Mills M, Emori C, Kumar P, Boucher Z, George J, Bolcun-Filas E bioRxiv. 2024; .

PMID: 38352597 PMC: 10862846. DOI: 10.1101/2024.02.02.578648.

The dual role of p63 in cancer.

Xu Y, Yang X, Xiong Q, Han J, Zhu Q Front Oncol. 2023; 13:1116061.

PMID: 37182132 PMC: 10174455. DOI: 10.3389/fonc.2023.1116061.

The Emerging Role of m6A Modification in Endocrine Cancer.

Ji X, Wang Z, Sun W, Zhang H Cancers (Basel). 2023; 15(4).

PMID: 36831377 PMC: 9954123. DOI: 10.3390/cancers15041033.

A Systemic and Integrated Analysis of p63-Driven Regulatory Networks in Mouse Oral Squamous Cell Carcinoma.

Glathar A, Oyelakin A, Nayak K, Sosa J, Romano R, Sinha S Cancers (Basel). 2023; 15(2).

PMID: 36672394 PMC: 9856320. DOI: 10.3390/cancers15020446.

References

Ihrie R, Marques M, Nguyen B, Horner J, Papazoglu C, Bronson R . Perp is a p63-regulated gene essential for epithelial integrity. Cell. 2005; 120(6):843-56. DOI: 10.1016/j.cell.2005.01.008. View

Kujala E, Makitie T, Kivela T . Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44(11):4651-9. DOI: 10.1167/iovs.03-0538. View

Flores E, Tsai K, Crowley D, Sengupta S, Yang A, McKeon F . p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002; 416(6880):560-4. DOI: 10.1038/416560a. View

Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A . p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999; 398(6729):708-13. DOI: 10.1038/19531. View

Mooy C, Luyten G, de Jong P, Luider T, Stijnen T, van de Ham F . Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol. 1995; 147(4):1097-104. PMC: 1871011. View

Perez-Losada J, Wu D, Delrosario R, Balmain A, Mao J . p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene. 2005; 24(35):5521-4. DOI: 10.1038/sj.onc.1208799. View

Flores E, Sengupta S, Miller J, Newman J, Bronson R, Crowley D . Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005; 7(4):363-73. DOI: 10.1016/j.ccr.2005.02.019. View

Serber Z, Lai H, Yang A, Ou H, Sigal M, Kelly A . A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol. 2002; 22(24):8601-11. PMC: 139862. DOI: 10.1128/MCB.22.24.8601-8611.2002. View

Ihrie R, Attardi L . A new Perp in the lineup: linking p63 and desmosomal adhesion. Cell Cycle. 2005; 4(7):873-6. DOI: 10.4161/cc.4.7.1836. View

10.

Hildebrandt T, Preiherr J, Tarbe N, Klostermann S, van Muijen G, Weidle U . Identification of THW, a putative new tumor suppressor gene. Anticancer Res. 2000; 20(5A):2801-9. View

11.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

12.

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson R . p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999; 398(6729):714-8. DOI: 10.1038/19539. View

13.

Luyten G, Naus N, Mooy C, Hagemeijer A, Kan-Mitchell J, van Drunen E . Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer. 1996; 66(3):380-7. DOI: 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F. View

14.

Yang A, Kaghad M, Wang Y, Gillett E, Fleming M, Dotsch V . p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998; 2(3):305-16. DOI: 10.1016/s1097-2765(00)80275-0. View

15.

Paraoan L, Gray D, Hiscott P, Ebrahimi B, Damato B, Grierson I . Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type. Exp Eye Res. 2006; 83(4):911-9. DOI: 10.1016/j.exer.2006.04.016. View

16.

Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-9. DOI: 10.1038/387296a0. View

17.

Spagnolo F, Caltabiano G, Queirolo P . Uveal melanoma. Cancer Treat Rev. 2012; 38(5):549-53. DOI: 10.1016/j.ctrv.2012.01.002. View

18.

Albert D . The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol. 1997; 123(6):729-41. DOI: 10.1016/s0002-9394(14)71119-5. View

19.

Oliner J, Pietenpol J, Thiagalingam S, Gyuris J, Kinzler K, Vogelstein B . Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993; 362(6423):857-60. DOI: 10.1038/362857a0. View

20.

Sun Y, Tran B, Worley L, Delston R, Harbour J . Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci. 2005; 46(5):1561-4. DOI: 10.1167/iovs.04-1362. View